Clinical Trials Sponsored by Gruppo Italiano MEsotelioma

Total 229 results

Gruppo Italiano MEsotelioma

Unknown

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Mesothelioma

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fondazione Italiana Linfomi

Recruiting

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

COVID-19 | Chronic Lymphocytic Leukemia | Indolent B-Cell Non-Hodgkin Lymphoma

Italy
Gruppo Italiano Mammella (GIM)

Unknown

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Breast Cancer

Italy
Gruppo Italiano Malattia Diverticolare

Unknown

Registro Malattia Diverticolare (Registry of Diverticular Disease) (REMAD)

Diverticulitis | Diverticulum, Colon
Gruppo Italiano Studio Linfomi

Completed

A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma

Multiple Myeloma

Italy
Gruppo Italiano Studio Linfomi

Completed

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy (NHLPal)

Non Hodgkin's Lymphoma | Chemotherapy-Induced Nausea and Vomiting

Italy
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Completed

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

Non Hodgkin's Follicular Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Unknown

Lenalidomide Plus Rituximab (R) in Non Follicular NHL

Indolent Non Hodgkin Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Unknown

Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Stage A(0) | Chronic Lymphocytic Leukemia Stage A(I) | Chronic Lymphocytic Leukemia Stage A(II)

Italy
Gruppo Italiano Studio Linfomi

Unknown

Gonadal Toxicity in Women With Hodgkin Lymphoma (FertHD)

Hodgkin Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Completed

Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders

Chronic Lymphocytic Leukaemia

Italy
Gruppo Italiano Studio Linfomi

Unknown

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Multiple Myeloma

Italy
Gruppo Italiano Studio Linfomi

Completed

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Italy
Gruppo Italiano Studio Linfomi

Completed

HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy

High-Grade Lymphomas

Italy
Gruppo Italiano Studio Linfomi

Completed

Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) (HD2000)

Advanced Hodgkin Disease

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Minimal Residual Disease | AML, Adult
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Refractory Lymphoma | Relapse | B-cell Non Hodgkin Lymphoma

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS)

Chronic Lymphocytic Leukemia | High Risk CLL

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Chemotherapy | Leukemia, Acute Lymphoblastic

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax (ENABLE)

Acute Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients

Chronic Lymphocytic Leukemia | CLL

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies

Hematologic Malignancies

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Acute Lymphoblastic Leukemia, in Relapse | Philadelphia-Positive ALL

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches

Acute Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). (PROPHECY)

Myeloproliferative Neoplasm
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)

Chronic Lymphoid Leukemia | Large-B-cell Diffuse Lymphoma

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Acute Lymphoid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (V-FIRST)

Acute Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia (LLC1114)

Adult Patients | Chronic Lymphocyte Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Complete Hematologic Remission (CHR) | Persistent/Recurrent Minimal Residual Disease (MRD)

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Terminated

Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML) (AML1617)

Acute Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Terminated

Retrospective Evaluation of CML Patients in the National Compassionate Program

Chronic Myeloid Leukemia | Philadelphia Positive

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients (LAL1104)

Leukemia, Lymphoblastic, Acute

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy (APL0511)

Pregnancy | Acute Promyelocytic Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Use of nMoABs for the Treatment of COVID-19 in Patients With HM.

Covid19 | Hematological Malignancy

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib (LLC1618)

Chronic Lymphocytic Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase (CML0912)

Chronic Phase Philadelphia Positive | BCR-ABL Positive | Chronic Myeloid Leukaemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

AML, Adult

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML0408)

Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate (LAL1913)

Secondary | De Novo | Untreated Philadelphia Positive Acute Lymphoblastic Leukemia | Low-dose Corticosteroids Pretreatment

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. (ITP0511)

Thrombocytopenia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. (CLL0911)

B-cell Lymphoid Leukemia | Young Patients

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Germany, Italy, Austria, Iraq, United States, Brazil, China, Malaysia, Netherlands
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia (LAL0904)

Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults (LAL1610)

Acute Lymphoblastic Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

GIMEMA CLL0809 Study (BendOfa) (BendOfa)

Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

Immune Thrombocytopenia

Italy

Clinical Trials Sponsored by Gruppo Italiano MEsotelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations